MONISTAT® provides the broadest treatment of yeast infections1, more than Diflucan® and Terazol®. Recent data from ISSVD shows that miconazole, the active ingredient in MONISTAT®, is the only recommended azole treatment for C. glabrata, the most prevalent non-albicans yeast species.
In fact, some national health plans now recommend OTC treatment with miconazole/MONISTAT® before a prescription. Get exclusive savings for your patients.
The chart below shows the appropriate non-compounded prescription or over-the-counter treatment for your patients with yeast infections according to the ISSVD
Recommend MONISTAT® to treat your patients’ yeast infections
Finding the best treatment plan for your patients has never been more convenient. The Vulvovaginal Candidiasis app from the International Society for the Study of Vulvovaginal Disease (ISSVD) has been designed to be used during patient visits and includes such features as:
- a treatment-by-type algorithm for each yeast species
- facts and images to help distinguish between different types of yeast species
- information about diagnosis and treatment options, including dosing
- and much more
The ISSVD app is available for a small fee from the App Store.
Order valuable MONISTAT® samples, coupons, and in-office resources for your patients and your practice.
*of all non-compounded drug products Diflucan® is a registered trademark of Pfizer Inc. and Terazol® is a registered trademark of Johnson & Johnson
REFERENCES: 1. Richter SS et al., Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol. 2005;43(5):2155-2162.